XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...

Related Keywords

United States ,Margaret Koziel ,Tragiannidisa Acinetobacter ,Pavel Raifeld ,Innoviva Inc ,Securities Exchange ,National Review Drug Discovery ,Drug Administration ,Jolla Pharmaceutical Company ,Entasis Therapeutics Inc ,World Health Organization ,Exchange Commission ,Nasdaq ,International Journal Of Infectious Disease ,Centers For Disease ,Glaxo Group Limited ,Yuk National Prevalence ,Innoviva Specialty Therapeutics Inc ,Urgent Public Health Threat In United States ,Innoviva Specialty Therapeutics ,Chief Executive Officer ,Infectious Disease ,Chief Medical Officer ,Disease Control ,Full Prescribing Information ,Specialty Therapeutics ,Specialty Therapeutic ,Long Acting Beta ,Collaboration Agreement ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Single Pathogen Antibacterial ,National Review Drug ,International Journal ,Safety Of Sulbactam ,Durlobactam Versus Colistin ,Non Inferiority Clinical Trial ,Published May ,Loading Dose Colistin ,Carbapenem Resistant Acinetobacter ,Critically Ill ,Risk Factors ,Clinical Presentation ,Antibiotic Resistance ,Resistant Acinetobacter ,Health Organization ,Markets ,